Percentage of patients meeting quality measures and the modeled rates of change for quality measures during phase 2 (end of year 1 to end of year 2) of the intervention*
 |
-
*Quality measures were calculated as the number who satisfied the measure/(number eligible−number not satisfied with an exception).
-
†Rates of change were derived from the linear regression models with autoregressive errors when necessary as described in the Methods section.
-
‡Performance for the cervical cancer screening measure could not be calculated accurately prior to January 2008 because of missing date information for exceptions.
-
§Because of studies questioning the value of aspirin for primary prevention, this recommendation and the quality measure were discontinued for the practice, and the clinical decision support tool was turned off. As expected, performance declined to 84.2% by the end of phase 2.
-
ACE, angiotensin converting enzyme; ARB, angiotensin-receptor blocker; LDL-C, low-density lipoprotein cholesterol; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction.
